NP 001

Drug Profile

NP 001

Alternative Names: NP001

Latest Information Update: 15 Sep 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Neuraltus Pharmaceuticals
  • Developer Neuraltus Pharmaceuticals; University of Hawaii
  • Class Neuropsychotherapeutics; Small molecules
  • Mechanism of Action Immunomodulators; Macrophage modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Amyotrophic lateral sclerosis
  • Phase I Alzheimer's disease
  • Preclinical Ataxia telangiectasia; Dementia; Parkinson's disease

Most Recent Events

  • 13 Sep 2017 Phase-I clinical trials in Alzheimer's disease in USA (IV) (NCT03179501)
  • 12 Jul 2017 Neuraltus Pharmaceuticals completes enrolment in a phase II trial for Amyotrophic lateral sclerosis in USA and Canada
  • 09 Jun 2017 University of Hawaii and Neuraltus Pharmaceuticals plan a phase II trial for Alzheimer disease (NCT03179501)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top